The “event” these option players are presumably focused on is FDA acceptance for filing of the Daxi BLA resubmission, which must happen no later than this week (30 days from the FDA’s receipt the BLA resubmission, which occurred on 3/7/22, the day prior to the PR in #msg-168122007). However, I don’t think the FDA’s acceptance of the resubmission for filing will affect the share price much.
Note: The 6-month clock for the FDA review of the BLA resubmission started on 3/7/22.
All of that options activity amounted to nothing. I will not be commenting on options trading again, as I obviously have no idea what any of it means. Sorry for wasting the board's time.